Nuclear Medicine
Recently published international recommendations for use of SIR-Spheres® Y-90 resin microspheres
- Newest publication of its kind focused on Dosimetry
- Fills a major information gap across international clinical communities
- Supports best practices to treat patients collaboratively in a program-based system to improve patient outcomes
- Developed by 43 international and multidisciplinary experts, including 23 members of the steering committee
The SIR-Spheres Advantage empowers practitioners by providing programs and tools to implement these consensus recommendations
Recommendation 23: "For selective ablative treatments, it is recommended to consider a higher specific activity, hence a lower number of microspheres." (Strong consensus)
Recommendation 17: "SIRT should be conducted as soon as possible after the simulation [...]" (Strong consensus)
Recommendation 46: "Post-SIRT dosimetry is recommended." (Strong consensus) / R21-22: "A personalized approach using dosimetry (partition model and/or voxel-based) is recommended for activity prescription." (Strong consensus)
Levillain, H., Bagni, O., Deroose, C.M. et al. International recommendations for personalized selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging 2021; 48(5): 1570-1584.
SIR-Spheres® Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) or unresectable metastatic liver tumors from primary colorectal cancer (mCRC) in patients refractory to or intolerant of chemotherapy.
SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.